Clinical trial
Randomized, Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity
NCT04101721 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity
- Lead sponsor
- Regeneron Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 30, 2019
- Completion date
- August 18, 2022
- Enrollment
- 127 (actual)
- Sites
- 52
Conditions
As the registry lists them; a condition with its own page is linked.